These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 8509145)
21. Variability of CR2 gene products is due to alternative exon usage and different CR2 alleles. Toothaker LE; Henjes AJ; Weis JJ J Immunol; 1989 May; 142(10):3668-75. PubMed ID: 2565927 [TBL] [Abstract][Full Text] [Related]
22. T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression. Masilamani M; von Seydlitz E; Bastmeyer M; Illges H Immunobiology; 2002 Dec; 206(5):528-36. PubMed ID: 12607728 [TBL] [Abstract][Full Text] [Related]
23. Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes. Illges H; Braun M; Peter HH; Melchers I Clin Exp Immunol; 2000 Nov; 122(2):270-6. PubMed ID: 11091285 [TBL] [Abstract][Full Text] [Related]
24. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Kulik L; Chen K; Huber BT; Holers VM Mol Immunol; 2011 Mar; 48(6-7):883-94. PubMed ID: 21269698 [TBL] [Abstract][Full Text] [Related]
25. Complement receptors regulate lipopolysaccharide-induced T-cell stimulation. Kaya Z; Tretter T; Schlichting J; Leuschner F; Afanasyeva M; Katus HA; Rose NR Immunology; 2005 Apr; 114(4):493-8. PubMed ID: 15804286 [TBL] [Abstract][Full Text] [Related]
26. Expression of the C3d-binding protein (CR2) from Candida albicans during experimental candidiasis as measured by lymphoblastogenesis. Fukayama M; Wadsworth E; Calderone R Infect Immun; 1992 Jan; 60(1):8-12. PubMed ID: 1370279 [TBL] [Abstract][Full Text] [Related]
27. Expression of human complement receptor 2 (CR2, CD21) in Cr2-/- mice restores humoral immune function. Marchbank KJ; Watson CC; Ritsema DF; Holers VM J Immunol; 2000 Sep; 165(5):2354-61. PubMed ID: 10946257 [TBL] [Abstract][Full Text] [Related]
28. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript. Sinha SK; Todd SC; Hedrick JA; Speiser CL; Lambris JD; Tsoukas CD J Immunol; 1993 Jun; 150(12):5311-20. PubMed ID: 8390533 [TBL] [Abstract][Full Text] [Related]
29. Identification of murine complement receptor type 2. Fingeroth JD; Benedict MA; Levy DN; Strominger JL Proc Natl Acad Sci U S A; 1989 Jan; 86(1):242-6. PubMed ID: 2783485 [TBL] [Abstract][Full Text] [Related]
30. Blimp-1 overcomes the block in IgM secretion in lipopolysaccharide/anti-mu F(ab')2-co-stimulated B lymphocytes. Schliephake DE; Schimpl A Eur J Immunol; 1996 Jan; 26(1):268-71. PubMed ID: 8566078 [TBL] [Abstract][Full Text] [Related]
32. Cell- and stage-specific chromatin structure across the Complement receptor 2 (CR2/CD21) promoter coincide with CBF1 and C/EBP-beta binding in B cells. Cruickshank MN; Fenwick E; Karimi M; Abraham LJ; Ulgiati D Mol Immunol; 2009 Aug; 46(13):2613-22. PubMed ID: 19487031 [TBL] [Abstract][Full Text] [Related]
33. The expression of membrane and secreted immunoglobulin during the in vitro differentiation of the murine B cell lymphoma CH12. Stockdale AM; Dul JL; Wiest DL; Digel M; Argon Y J Immunol; 1987 Nov; 139(10):3527-35. PubMed ID: 3500220 [TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways. Bouillie S; Barel M; Drane P; Cassinat B; Balbo M; Holers VM; Frade R Eur J Immunol; 1995 Sep; 25(9):2661-7. PubMed ID: 7589142 [TBL] [Abstract][Full Text] [Related]
35. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. Atkinson C; Song H; Lu B; Qiao F; Burns TA; Holers VM; Tsokos GC; Tomlinson S J Clin Invest; 2005 Sep; 115(9):2444-53. PubMed ID: 16127466 [TBL] [Abstract][Full Text] [Related]
36. Transcriptional regulation of the complement receptor 2 gene: role of a heterogeneous nuclear ribonucleoprotein. Tolnay M; Lambris JD; Tsokos GC J Immunol; 1997 Dec; 159(11):5492-501. PubMed ID: 9548489 [TBL] [Abstract][Full Text] [Related]
37. Lipopolysaccharide activation of murine splenocytes and splenic B cells increased the expression of aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator. Marcus RS; Holsapple MP; Kaminski NE J Pharmacol Exp Ther; 1998 Dec; 287(3):1113-8. PubMed ID: 9864300 [TBL] [Abstract][Full Text] [Related]
38. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. Takahashi K; Kozono Y; Waldschmidt TJ; Berthiaume D; Quigg RJ; Baron A; Holers VM J Immunol; 1997 Aug; 159(3):1557-69. PubMed ID: 9233655 [TBL] [Abstract][Full Text] [Related]
39. The murine complement receptor gene family. III. The genomic and transcriptional complexity of the Crry and Crry-ps genes. Paul MS; Aegerter M; Cepek K; Miller MD; Weis JH J Immunol; 1990 Mar; 144(5):1988-96. PubMed ID: 2307848 [TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. Kehrl JH; Thevenin C; Rieckmann P; Fauci AS J Immunol; 1991 Jun; 146(11):4016-23. PubMed ID: 1903417 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]